Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Two large studies compared posaconazole and fluconazole or itraconazole for prophylaxis in subjects undergoing allogeneic hematopoietic stem cell transplantation or subjects with acute myelogenous leukemia. To assess the impact of prophylaxis on colonization and the development of resistance in Saccharomyces yeasts, identification and susceptibility testing were performed with yeasts cultured at regular intervals from mouth, throat, and stool samples. Prior to therapy, 34 to 50% of the subjects were colonized with yeasts. For all three drugs, the number of positive Candida albicans cultures decreased during drug therapy. In contrast, the proportion of subjects with positive C. glabrata cultures increased by two- and fourfold in the posaconazole and itraconazole arms, respectively. Likewise, in the fluconazole arm the proportion of subjects with positive C. krusei cultures increased twofold. C. glabrata was the species that most frequently exhibited decreases in susceptibility, and this trend did not differ significantly between the prophylactic regimens. For the subset of subjects from whom colonizing C. glabrata isolates were recovered at the baseline and the end of treatment, approximately 40% of the isolates exhibited more than fourfold increases in MICs during therapy. Molecular typing of the C. albicans and C. glabrata isolates confirmed that the majority of the baseline and end-of-treatment isolates were closely related, suggesting that they were persistent colonizers and not newly acquired. Overall breakthrough infections by Candida species were very rare (∼1%), and C. glabrata was the colonizing species that was the most frequently associated with breakthrough infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491 · cited 1×
“glabrata also did not change; however, the MIC90s (but not the MIC50s) were two- to fourfold higher than those seen previously in a large survey of clinical isolates (14).”
ResultSanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398 · cited 1×
“The EOT isolate from subject 928, which exhibited high-level resistance to all three azoles, had no substitutions in Erg11p but did have a homozygous nonsense mutation in codon 178 of ERG3; such mutations confer high-level azole resistance (3, 15).”
BackgroundMucosal damage and neutropenia are required for Candida albicans dissemination
Koh, A. Y., Köhler, J. R., Coggshall, K. T., Van Rooijen, N., & Pier, G. B. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040035 · Cited by 360 · cited 1×
“Antifungal prophylaxis can reduce the incidence of candidemia through a reduction or the eradication of susceptible colonizing yeasts (7, 11, 13).”
BackgroundShifting patterns in the epidemiology of nosocomial Candida infections
Snydman, D. R. (2003) · Chest · doi:10.1378/chest.123.5_suppl.500s · Cited by 142
Cited by
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Self-citationSroussi, H. Y., Epstein, J. B., Bensadoun, R., Saunders, D. P., Lalla, R. V., Migliorati, C. A., Heaivilin, N., & Zumsteg, Z. S. (2017) · Cancer Medicine · doi:10.1002/cam4.1221 · Cited by 797
Jensen, R. H., Johansen, H. K., Søes, L. M., Lemming, L. E., Rosenvinge, F. S., Nielsen, L., Olesen, B., Kristensen, L., Dzajic, E., Astvad, K. M. T., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01763-15 · Cited by 77
Winston, D. J., Bartoni, K., Territo, M. C., & Schiller, G. J. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.04.017 · Cited by 73
Prospects for adoptive T-cell therapy for invasive fungal disease
Castellano-Gonzalez, G., Clancy, L. E., & Gottlieb, D. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000403 · Cited by 22
Metadata
- Authors
- Mann, P. A., McNicholas, P. M., Chau, A. S., Patel, R., Mendrick, C., Ullmann, A. J., Cornely, O. A., Patino, H., & Black, T. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-12
- Volume
- 53
- Issue
- 12
- Pages
- 5026-5034
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2166890510
- Cited by
- 81
- References
- 5
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species. https://app.cochat.ai/papers/10.1128/aac.01031-09
- The paper
- Mann, P. A., McNicholas, P. M., Chau, A. S., Patel, R., Mendrick, C., Ullmann, A. J., Cornely, O. A., Patino, H., & Black, T. A. (2009). Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01031-09
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.